a public good project by the
Synthesis
Company
of California

© 2026

Zsuzsanna Pápai | doi.page

0 works0 citations0 h-index

Zsuzsanna Pápai

Zrínyi Miklós National Defence University(HU)

Publications by Year

Research Areas

Sarcoma Diagnosis and Treatment, Genetic factors in colorectal cancer, Lung Cancer Research Studies, Clusterin in disease pathology, Colorectal Cancer Treatments and Studies

Most-Cited Works

→ Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer(2019)2,462 cited
→ Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1(2020)570 cited
→ Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial(2016)517 cited
→ Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial(2014)490 cited
→ Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial(2015)416 cited
→

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

(2023)

392 cited

→ Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial(2017)294 cited

→ Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas(2020)290 cited

→ Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy(2018)263 cited

→ Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial(2015)118 cited